Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients

Dr Jonge Biccler speaks to ecancer at ASH 2018 about relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients.
He explains that up to date information is important not only for patients, but also for providing the backbone of rational follow up programs.
Dr Biccler says that one of the main implications is that a focus on detecting relapses in patients who are unlikely to have them is not very cost efficient, when instead those resources could be used towards late toxicities such as cardiovascular disease.
What his interview about CNS lymphoma here: ecancer.org/conference/1057-a...
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php